FAK

Assets acting on this target.

Notes
original target text: FAK inhibitor

Focal adhesion kinase (FAK) is a non-receptor enzyme that sits inside cells at points where they attach to their surrounding structural scaffold, known as the extracellular matrix. When cells anchor themselves through surface proteins called integrins, FAK becomes activated and relays signals that influence how a cell moves, survives, and divides. In many solid tumors, FAK activity is elevated, helping cancer cells detach from a primary site, migrate, invade nearby tissue, and resist programmed cell death. FAK signaling also shapes the tumor microenvironment by influencing supporting cells such as fibroblasts and by contributing to an immune-suppressive milieu that shields tumors from immune attack. Because of this dual role in tumor cells themselves and in the surrounding tissue, blocking FAK is being explored as a strategy to reduce cancer spread and to make tumors more accessible to immune-based therapies. FAK is also implicated in fibrotic diseases, where excessive tissue scarring depends on similar adhesion and remodeling signals. Small-molecule inhibitors are designed to occupy the kinase's catalytic site, preventing it from transmitting these signals. This mechanism is relevant broadly across oncology, particularly in cancers with dense stromal tissue, and in fibrotic conditions where matrix remodeling drives disease progression.

Related mechanisms

FAK drugs compared

2 drugs, stage by indication
2 drugs acting on FAK: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)Avmapki Fakzynja Co-PackChugai Pharma, Pfizer, Verastem, Inc.small moleculeApprovedApproved in Ovarian Cancer
IfebemtinibBoehringer Ingelheim, InxMedsmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer

← all mechanisms